Search

Author/Creator Bassan, R.

1. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL). (12th June 2019)

Authors:
Gini, G.; Tani, M.; Bassan, R.; Tucci, A.; Ballerini, F.; Sampaolo, M.; Merli, F.; Re, F.; Annibali, O.; Liberati, A.; Visco, C.; Arcari, A.; Storti, S.; Fabbri, A.; Musuraca, G.; Zilioli, V.; Cox, M.; Luminari, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
427
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL. (23rd June 2022)

Authors:
Chiaretti, S.; Bassan, R.; Vitale, A.; Elia, L.; Piciocchi, A.; Viero, P.; Ferrara, F.; Lunghi, M.; Fabbiano, F.; Bonifacio, M.; Fracchiolla, N.; Di Bartolomeo, P.; Fazi, P.; De Propris, M. S.; Vignetti, M.; Guarini, A.; Rambaldi, A.; Foà, R.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
253
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS. (23rd June 2022)

Authors:
Bassan, R.; Chiaretti, S.; Della Starza, I.; Spinelli, O.; Santoro, A.; Elia, L.; De Propris, M. S.; Scattolin, A. M.; Paoloni, F.; Messina, M.; Audisio, E.; Marbello, L.; Borlenghi, E.; Zappasodi, P.; Vetro, C.; Martinelli, G.; Mattei, D.; Fracchiolla, N.; Bocchia, M.; De Fabritiis, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA. (23rd June 2022)

Authors:
Pane, F.; Castagnetti, F.; Luciano, L.; Russo Rossi, A.; Abruzzese, E.; Bassan, R.; Binotto, G.; Caocci, G.; Cimino, G.; Fazi, P.; Gozzini, A.; Lunghi, M.; Marasca, R.; Martino, B.; Bonifacio, M.; Cavazzini, F.; Paoloni, F.; Saglio, G.; Sica, S.; Tafuri, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
57
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search